CD8A and neoplasm: In addition, no protection against B16F10 re-challenge was observed in mice that rejected B16F10-OTI melanoma but that did not receive transfer of pmel-1 CD8+ T cells (Fig. 5b, c), directly implicating the participation of primed pmel-1 CD8+ T cells in the anti-tumor effects observed.